Jayant Vaidya and colleagues (July 10, p 91)1 suggest that a single dose of targeted intraoperative radiotherapy (TARGIT) should be considered as an alternative to external-beam radiotherapy delivered over several weeks for selected patients with breast cancer. We consider the results of this trial preliminary and immature since the follow-up is much too short to draw any conclusions about local recurrence rates.